Clinical Trials Browser

Phase 3 × Interventional × ALT-803 × Clear all

NCT06745908 2026-05-05

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung